Peer-Reviewed Publication
NPJ Precis Oncol2023;7(1):45.May 18, 2023Journal Article
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.
Heidi J Gray1, Payel Chatterjee2, Rachele Rosati2, Lauren R Appleyard2, Grace J Durenberger2, Robert L Diaz2, Hallie A Swan2, Danielle Peretti2, Maddy Pollastro2, Trevor Ainge2, Katannya Kapeli2, Shalini Pereira2, Astrid L Margossian2, Kalyan Banda3, Barbara A Goff1, Elizabeth M Swisher1, Brady Bernard2,4, Christopher J Kemp5, Carla Grandori6
1Division of Gynecology Oncology, University of Washington, Seattle, WA, USA.
2SEngine Precision Medicine, Seattle, WA, USA.
3Clinical Research Division, Fred Hutchinson Cancer Center and Division of Medical Oncology, University of Washington, Seattle, WA, USA.
4Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
6SEngine Precision Medicine, Seattle, WA, USA. cgrandori@senginemedicine.com.
Abstract
Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We describe a remarkable response to targeted therapy in a patient with platinum-resistant, advanced LGSOC who had failed standard-of-care chemotherapy and two surgeries. The patient was in rapid decline and entering hospice care on home intravenous (…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans